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Genome Sequencing of Autism-Affected Families Reveals
Disruption of Putative Noncoding Regulatory DNA
Tychele N. Turner,1 Fereydoun Hormozdiari,1 Michael H. Duyzend,1 Sarah A. McClymont,2
Paul W. Hook,2 Ivan Iossifov,3,4 Archana Raja,1,5 Carl Baker,1 Kendra Hoekzema,1 Holly A. Stessman,1
Michael C. Zody,4 Bradley J. Nelson,1 John Huddleston,1,5 Richard Sandstrom,1 Joshua D. Smith,1
David Hanna,1 James M. Swanson,6 Elaine M. Faustman,7 Michael J. Bamshad,1,8
John Stamatoyannopoulos,1 Deborah A. Nickerson,1 Andrew S. McCallion,2 Robert Darnell,4,5,9
and Evan E. Eichler1,5,*
We performed whole-genome sequencing (WGS) of 208 genomes from 53 families affected by simplex autism. For the majority of these
families, no copy-number variant (CNV) or candidate de novo gene-disruptive single-nucleotide variant (SNV) had been detected by mi-
croarray or whole-exome sequencing (WES). We integrated multiple CNV and SNV analyses and extensive experimental validation to
identify additional candidatemutations in eight families.We report that compared to control individuals, probands showed a significant
(p¼ 0.03) enrichment of de novo and private disruptivemutations within fetal CNSDNase I hypersensitive sites (i.e., putative regulatory
regions). This effect was only observed within 50 kb of genes that have been previously associated with autism risk, including genes
where dosage sensitivity has already been established by recurrent disruptive de novo protein-coding mutations (ARID1B, SCN2A,
NR3C2, PRKCA, and DSCAM). In addition, we provide evidence of gene-disruptive CNVs (in DISC1, WNT7A, RBFOX1, and MBD5), as
well as smaller de novo CNVs and exon-specific SNVs missed by exome sequencing in neurodevelopmental genes (e.g., CANX, SAE1,
and PIK3CA). Our results suggest that the detection of smaller, often multiple CNVs affecting putative regulatory elements might
help explain additional risk of simplex autism.Introduction
The underlying genetic etiology of autism (MIM: 209850)
has been an area of intense focus and has benefited consid-
erably from advances in sequencing technology. On the
basis of twin studies1,2 and syndromic forms of the dis-
ease,3,4 autism is known to have a genetic component.
With the application of exome sequencing and copy-num-
ber variation (CNV) microarrays to large collections of in-
dividuals with autism, the genetic architecture of autism
has become clearer. Rare and, in particular, de novo vari-
ants that disrupt the protein-coding portions of genes
and large CNVs are now estimated to contribute to 30%
of the diagnoses of simplex autism.5 In addition, another
7% of cases have been attributed to variants in genes
with a residual variation intolerance score (RVIS)6 < 50,
private to a family, and inherited from the mother.7 One
strategy for solving the remaining ~60% is to explore the
genome for genetic variants of large effect in families
who are already known to be negative for any obvious
potential causal variation (de novo likely gene-disruptive
[LGD] mutations or large CNVs).
Whole-genome sequencing (WGS) is increasingly
becoming more affordable,8 providing access to a more
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58 The American Journal of Human Genetics 98, 58–74, January 7, 20available with previous genomic technologies, including
exome sequencing, SNP microarrays, and array compara-
tive genomic hybridization (aCGH), especially within
noncoding and potentially regulatory9,10 regions of the
genome.11 Previous publications have suggested that
most of the protein-coding sequence is covered sufficiently
well by WGS,8 which actually provides better coverage12
than WES technology. Early comparisons, however, were
limited. A study of individuals with intellectual disability,
for example, made a comparison by using different plat-
forms, i.e., exomes generated by SOLiD or genomes
sequenced with Complete Genomics technology. The au-
thors reported a dramatic increase in diagnostic yield as
high as 42% for individuals who were previously negative
formicroarrayor exome sequencing,12 although itwas diffi-
cult to disentangle these differences from sequence and
coverage differences. Another study compared both Illu-
mina WES and WGS but was limited to six individuals.13
Finally, a more recent analysis of exome and genome
sequencing provided a comparison of multiple exome and
genome platforms but focused only on a subset of clinically
relevant genes14 as opposed to the whole genome.
In the present study, we specifically compared WGS on
the Illumina HiSeq X Ten platform to WES on the
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Figure 1. SNV and Indel Analysis
(A) Venn diagram of SNV calls from
FreeBayes and GATK and Venn diagram
of indel calls from FreeBayes, GATK, and
Platypus.
(B) Concordance by sample between
variant calls from FreeBayes, GATK, or their
intersection (FreeBayes and GATK) and
exome-chip data. Variants shown are those
passing filters. These data were available for
all samples (n ¼ 232,961 variants, of which
44,732 were identified in the genome VCF
file). SNP concordance with exome SNPmi-
croarrays was 99.80%5 0.03%, 99.90%5
0.01%, and 99.95%5 0.03% for FreeBayes,
GATK, and the intersection of FreeBayes
and GATK call sets, respectively.on the same samples. There were two aims. The first was to
understand the yield and technological limitations of both
WGS and WES approaches in detection of SNVs and CNVs
on a sufficiently large sample collection. The second was to
assess whether there is any genetic signal for rare and pri-
vate noncoding regulatory mutations in individuals with
idiopathic autism. Using the Illumina HiSeq X Ten plat-
form, we initially focused on 160 individuals from 40
quads with a single proband with autism for which no
likely pathogenic CNV or SNV had been originally identi-
fied in 39 families (phase I). We performed a follow-up
study on another 13 trios with a single autistic proband
and three control families by using standard HiSeq 2000
technology (phase II) in order to increase power.Material and Methods
Phase I families (n ¼ 39) for whom no de novo LGD muta-
tions5,15–18 or large CNVs19,20 had been observed in the proband
in previous exome and SNP microarray analyses (Figure S1) were
selected for WGS from the Simons Simplex Collection (SSC). In
addition, one family with a known LGD mutation served as a
‘‘control’’ family for variant detection. We were blinded to
this sample initially given that families were selected at the
Simons Foundation, and when we detected the event (splice siteThe American Journal of Humin TCF7L2 [MIM: 602228] in proband
13069.p1), we reported to Simons, and
they informed us that it was already
known. Genomic DNA derived from blood
was sequenced to an average depth of
31.13 5 4.53 (Figure S2A) with an Illu-
mina HiSeq X Ten sequencer at the New
York Genome Center (full statistics are
shown in Tables S1–S4 and Figure S2). We
evaluated the quality of each genome by
mapping WGS reads with mrsFAST21 to
the human reference genome (GRCh37,
1000 Genomes), estimating copy number
across the entire genome in 500 bp win-
dows (100 bp sliding), and calculating
the proportion of known copy-number-
invariant regions that were properly calledas copy number 2 (diploid) in each genome. The analysis identi-
fied four samples (11572.s1, 12175.s1, 12568.s1, and 13023.mo)
that did not meet our threshold of >85% ‘‘diploidy’’ (Figure S3A).
We used mitochondrial-genome characterization and KING22
analysis on nuclear genome SNV data to confirm all familial rela-
tionships. For themitochondrial genome, we identified an average
of 25 inherited events per family (Tables S5 and S6) and a trend
toward excess heteroplasmy in probands (n ¼ 4) rather than sib-
lings (n ¼ 2) (one-sided Fisher’s p ¼ 0.34, odds ratio [OR] ¼
2.09). We also sequenced 13 trios from the SSC and three control
trios from the National Children’s Study (phase II) locally to a
median mapped coverage of 513 on an Illumina HiSeq 2000 in-
strument. Once again, autism trios were selected if they contained
no large CNVs according to an aCGH platform23 or any LGD
events revealed through exome sequencing. Between the time
the phase II samples were sequenced and this study, it was deter-
mined by array that one of these families already contained a
known event in TMLHE (MIM: 300777) in proband 11000.p1.24
The institutional review board (IRB) of the University of Washing-
ton (IRB 46179) approved this study.
We called SNVs in the phase I genomes by using the Genome
Analysis Toolkit v.3.2-2 (GATK best practices) HaplotypeCaller25,26
and FreeBayes v.0.9.14-20-g5dc4d5e (Figure 1)27 in addition to
Platypus28 to potentially improve indel sensitivity. Private SNVs
and indels were defined as those identified by GATK and FreeBayes
(intersection) as having an allele count equal to 1 in parents in
this study and not present in dbSNP build 138. De novo SNV andan Genetics 98, 58–74, January 7, 2016 59
1 10 100 1000 
CNV size (kb) 
A
0.
0
0.
2
0.
4
0.
6
0.
8
D
en
si
ty
deletions
duplications
B 
read pair, read 
depth, and split 
read 
read pair, mobile 
element insertions 
read depth 
4.8% 
47.7% 
32.1% 
8.3% 
0.1% 
6.9% 
0.2% 
Figure 2. CNV Analysis
(A) Venn diagram of CNV calls from dCGH, GenomeSTRiP, and VariationHunter.
(B) Density of size for deletions and duplications. CNVs were initially merged if they had at least 25% reciprocal overlap and their break-
points were <1,500 nucleotides away from each other at both ends. To get a very minimal set, we subsequently merged CNVs by using a
greedy merge in BEDTools.indel discovery was achieved with software DNMFilter29 and
TrioDeNovo.30 In the phase II genomes, reads were mapped with
BWA-mem v.0.6.131 against GRCh37, and SNVs were called with
GATK v.2.7-2 UnifiedGenotyper. Variant quality-score recalibration
was applied and excluded tandem repeats, segmental duplications,
and dbSNP 129 positions falling in or before release 129. Samples
were split into trio variant call format (VCF) files containing entries
formother, father, andproband fromeach family. Potential denovo
SNVswere selected if thealternateallele count in theparentswas<2,
and a subset of high-confidence SNVs were selected for validation
by molecular inversion probe (MIP) resequencing32 after the call
was observed with the Integrated Genomics Viewer.33 We used
ForestDNM34 on each trio to select putative de novo variants. Vari-
ants with a score > 0.7 were considered high-confidence variants
and included in the analysis. For de novo indels, we additionally
required an allele balance in the proband of 0.25–0.75, no alternate
reads present in the parents, and a minimum alternate allele count
of5 intheproband.WeusedSeattleSeqAnnotation138.835 toanno-
tate SNVs and indels.
We called CNVs in phase I genomes by using digital compara-
tive genomic hybridization (dCGH),36 GenomeSTRiP,37 and
VariationHunter38 (Figure 2). We merged all CNV calls to a
minimal set by combining events with at least 25% reciprocal
overlap and breakpoints that were <1,500 nucleotides from each
other on both ends. This was applied uniformly to all samples
and merged most CNVs, although a few remained unmerged
because of separation by segmental duplications or large repeats.
For exome-genome comparisons, we used exome calls from
XHMM39 and CoNIFER40 as described previously.7 For phase II ge-
nomes, CNV calling was limited to VariationHunter (trio-aware
CommonLAW)38 and GenomeSTRiP.37
Genic, putative regulatory and repeat-associated variants were
annotated with SAVANT.41 Minor allele frequency was estimated
with dbSNP42 build 138, and a CNV morbidity map was estab-
lished on the basis of 29,085 case and 19,584 control individuals
in whom large (>100 kb) events had been characterized.43 SNP
and CNV genotypes were determined with the Illumina Human
Exome 12 v.1.2 exome chip, Illumina whole-genome SNPmicroar-60 The American Journal of Human Genetics 98, 58–74, January 7, 20ray data,19 and comparison to exomes (NimbleGen SeqCap EZ
Exome Kit v.2 [based on UCSC Genome Browser hg19] and Illu-
mina sequencing) for which BAM and VCF files were available.7
DNase I hypersensitive sequencing sites were determined on the
basis of sequencing of normal human fetal CNS tissues, including
13 brain samples (ages: post-conception days 85–142) and five
spinal-cord samples (ages: post-conception days 87–113). After
sequencing, the reads were aligned to the human genome, and
peaks were called with the Hotspot algorithm44 using a false-dis-
covery rate (FDR) of 1%. Herein, references to putative regulatory
regions refer to these CNS DNase I sites, and putative regulatory
variants were considered to be those falling within these regions
or with a phyloP score > 4 according to the USCS 46-way align-
ment. De novo SNVs and indels identified in autistic individuals
were collected from the literature5,7,15–18,32,45 and re-annotated
together. Testing for enrichment of de novo events was performed
as described previously32 for LGD, missense, and combined LGD
and missense events. A high-confidence set of 57 genes associated
with autism risk was generated by the selection of genes with three
or more de novo missense and/or LGD events in autistic individ-
uals, one or fewer de novo missense events, and no LGD muta-
tions in control individuals,5,7 as well as a p value< 0.01 in at least
one of the three tests. Enrichment of noncoding putative regula-
tory regions was tested within regions including and around genes
where de novo mutations had been identified. These regions
included the transcription start to the transcription stop and
extended out from the gene by a given distance (d).
We attempted validation on 691 candidate de novo SNVs and
indels in phase I by using Sanger and Pacific Biosciences
sequencing. We focused on sites mapping to coding regions and
putative, noncoding regulatory elements. In phase II, we used
MIP resequencing to validate a subset of putative de novo SNVs
and indels.32 In particular, we made MIP pools for each trio indi-
vidually and ran mother, father, and proband. Events detected
by both GATK and FreeBayes showed the highest validation rate
(VR ¼ 89.1%); these were followed by events detected only by
GATK (VR¼ 28.9%) and finally events detected by FreeBayes alone
(VR ¼ 10.6%) (Table S7). DNMFilter consistently outperformed16
TrioDeNovo for de novo calling within trios. Events called by both
DNMFilter and TrioDeNovo had the highest rate (VR ¼ 97.8%),
and these were followed by those only called by DNMFilter
(VR ¼ 65.5%) and finally events called only by TrioDeNovo
(VR ¼ 52.0%) (Table S7). For exonic regions, there were a total of
141 experimentally validated de novo mutations in 80 children.
To look at various features important in de novo validation, we
performed analysis with random forests46 and conditional infer-
ence trees,47 similar to the analysis we performed on variants
from exome sequencing.7
We used two different approaches to validate CNVs. First, we uti-
lized available whole-genome Illumina SNP microarray data and
exome-chip data and applied Corrected Robust Linear Model
with Maximum Likelihood Classification (CRLMM) software48,49
to generate probe-level copy-number estimates as described previ-
ously.7 We compared different thresholds on the basis of the num-
ber of SNP microarray probes intersecting a CNV (R5, R10,
or R20) and assessed ~10% of all CNVs with this approach. Site
VRs (whether the site was confirmed in at least one person) were
91.3%, 96.8%, and 97.9% for deletions and 85.6%, 94.4%, and
95.2% for duplications at the R5, R10, and R20 thresholds,
respectively. Genotype concordance, however, was significantly
reduced at 60.9% (R5 probes), 67.7% (R10 probes), and 65.7%
(R20 probes) for deletions, whereas duplications had a genotype
concordance of 40.6% (R5 probes), 49.6% (R10 probes), and
68.9% (R20 probes).
In the second approach, we designed a customized microarray
(Agilent) for aCGH validation. We targeted 2,002 CNV regions,
including all candidate de novo CNVs and all rare, inherited
events that had a frequency % 4 and that either overlapped an
exon or CNS DNase I hypersensitive site or were in a highly
conserved region with a maximum phyloP score > 4. The
43180K Agilent microarray contained 166,175 probes targeting
the CNV regions. VRs were very high for events detected by all
three callers (98.5%). For unique calls, dCGH showed the highest
validation (92.2%) and was followed by GenomeSTRiP (89.1%)
and lastly VariationHunter (38.2%). We note that sensitivity
ranged by a factor of 3 for these different callers, reflecting the
challenge of maintaining a low FDR as part of CNV discovery.
Moreover, it is often difficult to validate events < 2 kb in size
by aCGH.
We identified 12 CNS DNase I hypersensitive sites within the
14 kb deletion of DSCAM (MIM: 602523) in family 11572, and
all were selected for functional testing. Nine sequence intervals
(150–630 bp), encompassing either one or two of the 12 CNS
DNase I hypersensitive sites within the interval, were synthesized
as gBlocks (IDT) to be flanked by modified Gateway arms.50 Se-
quences separated by %100 bp were grouped into a common in-
terval for the transgenic assay. The gBlocks were cloned (Gateway
LR Clonase) into the pTEA vector, a version of pT2cfosGW51,52
modified to express the red fluorescent reporter tdTomato, for in-
jection into zebrafish embryos. Zebrafish were maintained as pre-
viously described.53,54 At least 150 embryos were injected per
construct at the 1- to 2-cell stage with tol2 transposase RNA as pre-
viously described.51,52 Injected (mosaic) embryos were screened
for tdTomato expression at 48 hr post fertilization (hpf). Mosaic
embryos were scored positive if they had robust tdTomato CNS
expression. The >20% threshold is an empiric cutoff used for
determining the likelihood that injected constructs will show
that same tissue expression when it is transmitted through the
germline. Because all constructs showed CNS expression in
>20% embryos, the results are consistent with strong drivers ofThe Aexpression. Embryos were then live imaged at 48 hpf with a Nikon
AZ100 Multizoom microscope with NIS-Elements AR 3.2 64 bit
software.Results
SNV and Indel Discovery and Analysis
Applying two SNV and indel callers to WGS data, we iden-
tified 1,563,113 private or rare variants detected in the
intersection of GATK and FreeBayes in probands and sib-
lings. WGS SNP call sets were high according to a compar-
ison to SNP microarrays (>99%) (Figure 1B). WES call sets
showed lower concordance with WGS data (99.08% 5
0.83%) than with SNP microarray genotypes (99.96% 5
0.02%) (Figure S4). Although we observed no significant
difference between probands and siblings in terms of
overall variant counts (Table S8), probands showed a slight
excess of highly conserved missense variants (phyloP > 4)
in genes associated with autism risk variants (ten in pro-
bands versus seven in siblings). We initially identified
5,609 de novo SNVs and indels by using DNMFilter
(70.1 5 12.0 variants per individual). De novo variants
showed evidence of nonrandom clustering (Figure S5),
and the number of new mutations significantly correlated
with paternal age (Figure 3A) as described previously.18,55
Application of a second caller, TrioDeNovo, discovered
an additional 2,341 variants (missed by DNMFilter), albeit
with a lower VR. In total, we detected 7,978 de novo
events (7,936 SNVs and 42 indels) and an overall VR of
75.2% for tested variants (Table S7). The most common
cause of false positives was under-calling in the parent
(which can be approximated by a probability score in
DNMFilter; see Figures S6–S10 and, for a full table with fea-
tures, Table S9).CNV Discovery and Analysis
We identified a total of 388,538 CNV events correspond-
ing to 9,917 distinct genomic regions in the 160 phase I
genomes. Overall, probands showed slightly more (n ¼
101,257) than siblings (n ¼ 95,727; one-sided paired
t test p ¼ 1.83 103). Leveraging available SNP microarray
data for 140 samples, we validated CNVs by using a
custom permutation test and CRLMM (see Material and
Methods, Figure S11, and Tables S10 and S11). Requiring
a minimum of ten SNP microarray probes, we obtained
site VRs of 96.8% for deletions and 94.4% for duplications,
although genotyping concordance was significantly lower
(Material and Methods). To further assess the validation of
rare and de novo events, we applied a targeted aCGH
approach. We tested 1,529 rare, inherited, and de novo
CNVs in all 80 probands and siblings (n ¼ 40 quads) and
obtained an overall VR of 91.9% (Table S12). We validated
five de novo CNVs in these families (two in probands and
three in siblings). The de novo events included an SAE1
(MIM: 613294) exonic duplication (52 kb) in proband
13874.p1 and a CANX (MIM: 114217) promoter andmerican Journal of Human Genetics 98, 58–74, January 7, 2016 61
Figure 3. Paternal Age and De Novo Events
(A) Paternal age for de novo SNVs and indels. Probands generally
have older fathers. The number of variants was significantly corre-
lated with paternal age (Pearson correlation p ¼ 7.9 3 109, r ¼
0.59). The data fit a linear trend (adjusted r2 ¼ 0.34) with
advancing paternal age (p ¼ 7.9 3 109) such that there are on
average 1.4 [0.98, 1.9] de novomutations for each year of a father’s
life. In this study, the father’s age at the time of the child’s birth
ranged from 29.4 to 57.9 years.
(B) Paternal age for de novo SNVs and indels within the exome.
The number of de novo events detected in each individual is
plotted against the father’s age when the individual was born.
Shown in blue are siblings, and in red are probands.exon 1 deletion (6 kb) in proband 14153.p1. Sibling
de novo events included ATP2C2 (MIM: 613082) and
TLDC1 deletions (84 kb) in sibling 13874.s1, PMAIP1
(MIM: 604959) and MC4R (MIM: 155541) duplications
(1.3 Mb) in sibling 13023.s1, and an EIF5B (MIM:
606086) deletion (6 kb) in sibling 12175.s1. Restricting
our analyses to the 3,193 de novo and private CNVs
(which were identified in only one family in our study
and had a frequency< 0.1% in 19,584 control individuals)
in probands (n¼ 1,589) and siblings (n¼ 1,604), we found
no significant difference in size, genic content, or trans-
mission bias between siblings and probands, possibly
because of the CNV exclusion criteria for probands (Table
S13). Considering all genic regions in the human genome,62 The American Journal of Human Genetics 98, 58–74, January 7, 20we found no enrichment of noncoding putative regula-
tory CNV events in probands (n ¼ 417 in probands versus
n ¼ 449 in siblings).
Exome versus Genome
Sequence coverage was predictably13,56 more uniform by
WGS (36.63 5 5.43) than by WES (81.23 5 38.63)
(Figure S12). WGS-only regions were higher in GC content
(60.4%5 0.2%, p < 2.2 3 1016) than were WES-only re-
gions (47.4% 5 0.1%) (Figure 4). WGS recovered 1,854
genes that were missing WES data for >90% of samples,
whereas WES detected only two genes (ATP6V1G3 and
SLCO1B1 [MIM: 604843]) that were missing WGS data
in>90%of samples (Figure 5).Consequently, SNVand indel
callingwithin exome targetswas alsomoreuniformbyWGS
(22,4645 578) than byWES (22,1725 3,207) (Figure 5). In
the genome, the variabilitywas primarily drivenby ancestry
(Figure S3B), and no such effect was seen in the exome
calls, which showed rather stochastic variability across sam-
ples. Combining the WES and WGS data, we identified
176,131 exonic SNV and indel events. Of these, 53.9%
were found by both WES and WGS, 35.2% were detected
by WGS, and 10.8% were detected by WES.
In general, WES-specific sites showed higher sequence
coverage (Wilcoxon p < 2.2 3 1016), but examination
of the unfiltered VCF files from WGS recovered most of
these (93.7%), suggesting that the exclusion was a result
of filters applied to the VCF files. Similarly, 78.9% 5
10.5% of WGS-specific sites within exome capture sites
could be recovered in the raw exome VCF files
(Figure S13). Ultimately, 3.1% and 3.0% of sites were
WES and WGS specific, respectively. We combined data
from our current study and from previously published
exome studies to obtain the most comprehensive set of
de novo variants in the protein-coding regions of these
samples (Table S14). There were 210 such variants, of
which 173 resided within the NimbleGen exome-capture
regions. Of these events, 105 (VR ¼ 93.3%, n ¼ 104 tested)
were detected by both exome and genome sequencing, 21
(VR ¼ 35.0%, n ¼ 20 tested) were detected by only exome
sequencing, and 47 (VR ¼ 37.1%, n ¼ 35 tested) were de-
tected only by genome sequencing. Overall, we estimate
1.8 5 1.2 validated de novo exonic mutations per child,
which is significantly higher than many of the earlier
exome reports. These findings highlight the value of
combining WGS and WES to maximize SNV sensitivity.
However, fully determining the extent will require much
larger sample sizes. With respect to CNVs, WES provided
no additional gain in sensitivity (Figures S4B and S14).
Moreover, events detected by WGS were 3-fold smaller
(10 5 24 kb, median ¼ 2 kb) than those detected by
WES analysis (38 5 64 kb, median ¼ 7 kb; Wilcoxon
p ¼ 1.4 3 107). Our comparison of CNV calls from
WGS and SNPmicroarrays also indicated detection of addi-
tional CNVs by WGS: 6,898 smaller CNVs less than 50 kb
were not detected by CNV calling in SNP microarrays
(Figure S15).16
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Figure 4. Exome versus Genome: GC Bias
(A) Percentage of GC content in exome-specific sequencing and genome-specific sequencing regions within the exome.
(B) Percentage of average GC content by sample of exome-specific sequencing and genome-specific sequencing regions within the
exome. Genome-specific regions are defined as those at>103 coverage in the genome and<103 coverage in the exome. Exome-specific
regions are defined as those at >103 coverage in the exome and <103 coverage in the genome. Genome-specific regions are higher in
GC content (Wilcoxon p < 2.2 3 1016).Smaller CNV and Noncoding Putative Regulatory
Mutations in Autism Genomes
In this study, we specifically focused our analysis on non-
coding de novo SNVs and indels. In particular, we
restricted our analysis to putative regulatory sites, defined
as sites in a fetal humanCNSDNase I hypersensitive region
and/or at a highly conserved base (phyloP score> 4, UCSC
46-way alignment). We attempted Sanger or Pacific Biosci-
ences validation on all such regulatory sites in phase I and
combined the validated events with all events identified inA
Figure 5. Exome versus Genome: Gene Coverage
(A) Number of genes that have regions covered in exome-specific seq
the number of samples in which they occur. Genome-specific regions
exome-specific regions add an additional ~40 kb. Genome sequencin
targeted by exome sequencing, whereas exome sequencing identified
genome sequencing. Among the genes ascertained only by WGS, th
AGAP2 (MIM: 605476), ARID1B, CACNA2D3 (MIM: 606399), DEAF
LAMC3 (MIM: 604349), MYO1E (MIM: 601479), PRKAR1B, RAN
606230), and TRIO.
(B) Density plots of the number of variants (intersection of FreeBay
genome sequencing. Shown is the uniformity of calls in the genome d
samples. Of note, exome data are exceedingly variable in the numbe
The Athe intersection of FreeBayes and GATK (VR ¼ 89.1%) to
generate a high-confidence de novo SNVand indel dataset.
These data contained 204 noncoding putative regulatory
events in probands and 171 in siblings, which did not
meet significance (p ¼ 0.07, paired t test) after we ac-
counted for paternal age.
Although it was underpowered, we repeated the analysis
by limiting to 57 genes where an excess of recurrent
de novo mutations had been identified in probands on
the basis of recent exome sequencing studies of familiesB
uencing or genome-specific sequencing regions of the exome and
of the exome add an additional ~2 Mb (5%) of sequence, whereas
g detected 1,854 genes missing sequences in >90% of individuals
only two genes missing sequences in>90% of samples targeted by
ose of interest in relation to autism include ACHE (MIM: 100740),
1 (MIM: 602635), EFR3A (MIM: 611798), FOXP1 (MIM: 605515),
BP17 (MIM: 606141), RUFY3 (MIM: 611194), SHANK3 (MIM:
es and GATK) called in the exome-by-exome sequencing and by
ata where only ancestry is a contributor to the difference between
r of variant calls.
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Table 1. Enrichment of Mutations in Putative Regulatory Elements
Variant
Category
Autism Control Fisher’s
One-
Sided
p Value
Confidence
Interval
Fisher’s
OR
Variant
Count
Genes Associated with
Autism Risk Variants
Variant
Count
Genes Associated with
Autism Risk Variants
Total 3,787 – 2,997 – – – –
Noncoding Putative Regulatory
d ¼ 10 kb 5 ARID1B (2), PRKCA, DSCAM,
SCN2A
0 – 0.05 [0.96, inf] inf
d ¼ 25 kb 6 ARID1B (2), NR3C2, PRKCA,
DSCAM, SCN2A
0 – 0.03 [1.22, inf] inf
d ¼ 50 kb 6 ARID1B (2), NR3C2, PRKCA,
DSCAM, SCN2A
0 – 0.03 [1.22, inf] inf
d ¼ 100 kb 8 ARID1B (2), NR3C2, PRKCA, PHYIN,
DSCAM, SCN2A, TRIO
1 DYRK1A (MIM: 600855) 0.04 [1.05, inf] 6.34
d ¼ 500 kb 21 ARID1B (2), CACNA1D (MIM:
114206), CHD2 (MIM: 602119),
MYO1E (MIM: 601479), NR3C2,
PRKAR1B, PRKCA, PYHIN1
(2; MIM: 612677), SCN2A,
SHANK3, WDFY3, DSCAM,
PRKAR1B, RFX7 (MIM: 612660),
SCN2A, SLC6A13 (MIM: 615097),
SRCAP (MIM: 611421), TRIO,
UNC45B (MIM: 611220)
9 DYRK1A (3), TMEM94,
CACNA1D, CHD2, CHD8
(MIM: 610528), RFX7,
UNC45B
0.08 [0.91, inf] 1.85
d ¼ 1 Mb 28 ARID1B (2), ASH1L (MIM: 607999),
CACNA1D, CHD2, CREBBP (2; MIM:
600140), MYO1E, NR3C2, NRXN1
(MIM: 600565), POGZ (MIM: 614787),
PRKAR1B, PRKCA, PYHIN1 (2), SCN2A,
SHANK3, WDFY3, AGAP2, DSCAM,
PRKAR1B, RFX7, SCN2A, SLC6A13,
SRCAP, TRIO, UBE3C (MIM: 614454),
UNC45B
18 CACNA1D, CHD2, CLASP1
(MIM: 605852), DYRK1A (3),
TMEM94 (2), LAMC3, PSME4
(MIM: 607705), SCN2A, TBR1
(MIM: 604616), WDFY3,
CHD8, RFX7, SRCAP, UBE3C,
UNC45B
0.3 [0.72, inf] 1.23
This table summarizes the counts of possible disruptive mutations (de novo SNVs or CNVs) in predicted regulatory regions between probands and unaffected
(control) siblings. The analysis is limited to genes associated with autism risk according to previous evidence of de novo LGD mutations in the coding region.
The nearest gene with a given distance (d) is indicated as described in the Material and Methods. Abbreviations are as follows: inf, infinity; and OR, odds ratio.affected by simplex autism5,32,57 (Table S15). We hypothe-
sized that these genes associated with autism risk might
harbor more noncoding putative regulatory variants in
probands given that such mutations would be more likely
to affect dosage, as has been observed for Mendelian dis-
eases.58 Because regulatory elements can exist at least as
far as 1 Mb11 away from the gene, we tested various dis-
tance intervals (d) on either side of the transcription start
and end of each gene. We consistently found an excess
of de novo SNV and indel variants in probands, although
none reached statistical significance (lowest p ¼ 0.27,
Fisher’s exact test).
We also examined CNVs for the same effect. Validation
by aCGH, SNP microarray, or PCR was attempted on all
de novo and private CNVs identified in the phase I ge-
nomes (n ¼ 2,002). From this high-confidence set, we
defined 1,202 validated de novo and private CNVs with
at least one DNase I hypersensitive base. As with SNVs,
we found a slight excess of events in probands at all dis-
tance intervals (lowest p value¼ 0.09 at d¼ 100 kb), which
contained five events in probands (DSCAM, FAT3 [MIM:
612483], PRKAR1B [MIM: 176911], TRIO [MIM: 601893],
and ZC3H4) but only a single event in siblings (PAX564 The American Journal of Human Genetics 98, 58–74, January 7, 20[MIM: 167414]). A combined analysis with de novo SNVs
and private CNVs showed greater enrichment around
genes where an excess of de novo protein-coding variants
had been identified. This occurred especially in proximity
to the gene (d ¼ 25 kb [p ¼ 0.12], d ¼ 50 kb [p ¼ 0.07], and
d¼ 100 kb [p¼ 0.06]). In order to increase power, we tested
for enrichment around autism-associated genes by using a
larger set of samples sequenced locally (phase II genomes).
We integrated genome sequence data from an additional
13 affected trios and 3 unaffected trios for a total of 53
autism genomes and 43 unaffected siblings or control indi-
viduals. We found modest yet statistically significant
enrichment of potentially disruptive events close to genes
associated with autism risk (d ¼ 25 kb [p ¼ 0.03], d ¼ 50 kb
[p ¼ 0.03], and d ¼ 100 kb [p ¼ 0.04]; varying d shown in
Table 1). Thus, three of the six tests showed nominal signif-
icance, and significance dropped off as distance increased.
The set includes de novo SNVs (Table 2) and CNVs (Table 2)
near DSCAM, SCN2A (MIM: 182390), TRIO, NR3C2 (MIM:
600983), and PRKCA (MIM: 176960) and multiple events
associated with ARID1B (MIM: 614556) (Figure 6). Replica-
tion of this effect is required and will be testable with larger
sample sizes in the future.16
Table 2. Variants of Interest in Autistic Individuals from 53 Families
Genomic HGVS (GRCh37) Individual Inheritance Valid Caller Dataset Type Gene Exonic Splice
Putative Regulatory
Variant RefSeq HGVS
ChrX: g.154770750_154784551del 11000.p1 MP Y^ VH phase II CDS TMLHE N NM_018196:
c.–1–9613_181þ4007del
Chr21: g.42016189_42030325del 11572.p1 MP Y D, GS, VH phase I NCS N DSCAM (d ¼ 10 kb)* –
Chr12: g.1948914_1984653del 11709.p1 FP Y GS, VH phase II CDS CACNA2D4 N NM_172364:
c.1720–150_2551þ991del
Chr6: g.157315964_157328116del 11709.p1 MP Y GS, VH phase II NCS N ARID1B (d ¼ 10 kb)* –
Chr2: g.166253120_166373394del 11709.p1 MP Y GS, VH phase II NCS CSRNP3 SCN2A (d ¼ 10 kb)* –
Chr1: g.231828151_231933482del 11712.p1 MP Y GS, VH phase II CDS DISC1 N NM_018662:
c.68–1421_1690–2372del
Chr2: g.149051133_149086337del 11712.p1 FP Y GS, VH phase II NCS N MBD5 (d ¼ 10 kb) –
Chr2: g.233396326G>A 11729.p1 DN Y GATK phase II CDS missense CHRND N NM_000751:
c.1007G>A; NP_000742:
p.Arg336Gln
Chr11: g.67926275G>A 11729.p1 DN Y GATK phase II CDS missense SUV420H1 N NM_017635:
c.1538C>T; NP_060105:
p.Ala513Val
Chr3: g.178916936G>A 11804.p1 DN Y GATK phase II CDS missense PIK3CA N NM_006218:
c.323G>A; NP_006209:
p.Arg108His
Chr3: g.13920617_13922554del 12793.p1 MP Y GS,VH phase I CDS WNT7A N NM_004625:
c.–1241_71þ626del
Chr4: g.148986808G>A 12793.p1 DN Y GATK phase I NCS N NR3C2 (d ¼ 25 kb)* –
Chr10: g.114901076G>A 13069.p1 DN Y GATK, F phase I ESS TCF7L2 N NM_001146274:
c.685þ1G>A
Chr6: g.157401254C>A 13111.p1 DN Y GATK phase II NCS N ARID1B (d ¼ 10 kb)* –
Chr11: g.131345836_131583798del 13122.p1 FP Y GS, VH phase II NCS LOC101929653 NTM –
Chr16: g.6908075_7079700del 13122.p1 MP Y GS, VH phase II NCS N RBFOX1 (d ¼ 10 kb) –
Chr5: g.14015350_14055499dup 13539.p1 MP Y D phase I NCS N TRIO (d ¼ 100 kb)* –
Chr5: g.122155926_122163623del 13825.p1 FP ND GS, VH phase II CDS SNX2 N NM_003100:
c.1212þ1208_1509þ282del
Chr15: g.25088705_25117621del 13825.p1 FP Y GS, VH phase II CDS SNRPN N NM_022805: c–13736_–578–14041del
Chr12: g.99020493T>C 13825.p1 DN Y GATK phase II CDS missense IKBIP N NM_153687: c.349A>G; NP_710154:
p.Met117Val
Chr19: g.47635921_47687660dup 13874.p1 DN Y D phase I CDS SAE1 N NM_005500: c.98þ1636_734–12830dup
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66 The American Journal of Human Genetics 98, 58–74, January 7, 20Finally, we focused on integrating all potential disease-
related CNV, SNV, and indel events in our set of 53
autism-affected families. In addition to identifying de
novo and private mutations in putative regulatory ele-
ments of genes associated with autism risk, we identified
and validated gene-disruptive CNVs in neurodevelopmen-
tal genes (DISC1 [MIM: 605210], WNT7A [MIM: 601570],
RBFOX1 [MIM: 605104], and MBD5 [MIM: 611472]). We
also validated smaller de novo CNVs and SNV exon-spe-
cific mutations missed by exome sequencing in likely
candidate genes (e.g., CANX, SAE1, and PIK3CA [MIM:
171834]) according to the literature. The evidence and sig-
nificance of each are discussed in detail below. Given that
autism involves a well-appreciated sex bias favoring males,
we considered the yield among four different proband-
sibling gender combinations (male-male, male-female,
female-male, and female-female) where applicable. In
this analysis (Table S16), families were scored as having a
candidate event in a gene associated with autism muta-
tional burden, a candidate event in another gene, other
events, or no events. Excluding two control families in
whom potential pathogenic exonic events had been
previously identified, we identified 16 families (31.3%)
containing largely private or de novo events within genes
previously associated with autism or neurodevelopmental
disease; nine families (17.6%) in particular carried poten-
tially high-impact variants (Figure 6). Among the latter,
at least five probands (9.8%) were deemed to carrymultiple
high-impact variants, often as a result of transmission from
both parents or of multiple de novo events.
In Vivo Functional Testing of DSCAM Deletion
Interval
Although DNase I hypersensitivity sites are enriched with
noncoding regulatory DNA, their functional potential
can only be determined through experimentation. We
selected one of the smallest CNVs (14 kb DSCAM deletion
interval from family 11572), which contained 12 CNS
DNase I hypersensitivity sites, and assayed its potential
to direct tissue-dependent reporter expression in a previ-
ously described transgenic zebrafish assay51,52 (see Material
and Methods). We synthesized nine sequence intervals
(150–630 bp), corresponding to either one or two of the
12 CNS DNase I hypersensitive sites within the interval
(Figure 7; see Material and Methods). Our analysis indi-
cated that all nine constructs directed reporter expression
in the CNS of 48 hpf G0 mosaic zebrafish embryos
(Table 3). Although the lower threshold for reporting
CNS positive expression only required signal to be detected
in R20% of injected embryos, all constructs comfortably
exceeded this threshold (range 49%–73%). Expression
was seen consistently across a variety of CNS structures,
including the forebrain, midbrain, hindbrain, spinal
cord, olfactory placodes, and amacrine cells (Figure 7).
We note that expression outside of the CNSwas not consis-
tently detected for any of the constructs, providing further
evidence of the specificity. These findings are consistent16
Figure 6. All Variants Shown for Each Family Were Validated by Appropriate Methods
(A) Family 14153. The events are a de novo exonic deletion of the promoter and first exon of CANX and two de novo missense SNVs in
CBL (MIM: 165360) and FAF2. The location of the de novo deletion is also shown with respect to CANX.
(B) Family 13874. The event is a de novo exonic duplication in SAE1. Furthermore, we provided a mock representation of the de novo
duplication with respect to SAE1.
(C) Family 12793. The event is a promoter and exonicWNT7A deletion passed from the mother to the male proband. As shown in the
mock representation of the inherited deletion, it removes the 50 UTR and the first exon ofWNT7A. This proband and the mother both
have macrocephaly, which is in concordance with maternally inherited deletion of WNT7A.
(D) Family 11572. The event is a DSCAM deletion encompassing CNS DNase I hypersensitive sites passed from the mother to the male
proband. This individual also suffers from nonfebrile seizures, in concordance with disruption of DSCAM.
(E) Family 13539. The event is a duplication upstream of TRIO. It encompasses CNS DNase I hypersensitive sites and was passed from the
mother to the male proband.
(F) Family 11804. A conserved missense de novo mutation (phyloP ¼ 2.57) was found in PIK3CA. This individual has macrocephaly,
which is in concordance with disruption of PIK3CA.
(G) Family 11712. We found a maternally inherited rare, private exonic deletion of parts of DISC1 and a 35 kb paternally inherited rare
intronic deletion ofMBD5. The deletion affectingDISC1 is around 150 kb, deletes a few coding exons of this gene, and is not seen in over
15,000 genotyped control individuals.
(H) Family 13122. We found two large rare deletions that intersect NTM and RBFOX1—one inherited from the father and the other in-
herited from the mother. The maternally inherited rare deletion is 240 kb and deletes most of the first intron of NTM. This is an
extremely rare deletion, given that it was not observed in over 15,000 control individuals. The paternally inherited rare deletion is
170 kb and deletes an intron of RBFOX1.
(I) Family 11709. We found three rare, private deletions affecting genes of interest. First, we found a 30 kb paternally inherited rare, pri-
vate exonic deletion of CACNA2D4. We also found two maternally inherited rare, private deletions that affect genes of interest. One is a
120 kb exonic rare and private deletion less than 5 kb downstream of SCN2A, and the other is a 12 kb rare deletion of an intron of
ARID1B.
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Figure 7. Functional Analysis of CNS DNase I Hypersensitivity Sites in the DSCAM Deletion
(A) Schematic of the 14 kb DSCAM deletion observed in family 11572. The diagram illustrates the 12 DNase I hypersensitivity sites (HSs)
contained within the deletion, as well as the nine sequence intervals encompassing them. These sequence intervals were tested for their
potential to direct reporter expression.
(B–D) Bright-field images of representative 48 hpf mosaic zebrafish embryos injected with DSCAM-6 (B), DSCAM-2 (C), and
DSCAM-1 (D).
(E–G) tdTomato expression in representative 48 hpf mosaic embryos injected with DSCAM-6 (E), DSCAM-2 (F), and DSCAM-1 (G).
Expression was seen in the forebrain (E–G), hindbrain (E–G), midbrain (E and F), spinal cord (F and G), and amacrine cells (F and G).with our hypothesis that the sequences within the 14 kb
DSCAM deletion have regulatory potential that affects
CNS biology. Analyses of reporter expression in stable
transgenic lines will be needed for further validating
this initial finding and refining our understanding of
the neuronal populations in which these sequences can
function.Discussion
In this study, we fully sequenced the genomes of 53 fam-
ilies who are affected by simplex autism and in whom
de novo LGD mutations and large CNVs had not been de-
tected by previous exome sequencing andmicroarray anal-
ysis. By this approach, we hypothesized that we would
identify disease-associated events mapping to noncoding
regions likely to affect gene regulation. We focused on de68 The American Journal of Human Genetics 98, 58–74, January 7, 20novo and rare inherited SNVs, indels, and CNVs identified
with multiple callers in an effort to establish a set of best
practices. It is critical to use a number of high-quality
callers to detect variation given that no caller, at this
time, is able to detect all relevant variants. In the case of
SNVs, we applied both FreeBayes and GATK. The benefits
of using multiple callers are twofold. First, when a variant
is found by both callers, the VR is very high (89.1%),
providing a very high-confidence set. Second, each caller
is able to detect variants that the other missed. In our study
of 40 quads, an additional 2,567 and 91 de novo and
133,058 and 57,974 private variant calls were detected by
GATK alone and FreeBayes alone, respectively. These addi-
tional calls will be critical for discovering disease-related
variants in affected individuals, although additional vali-
dation is required. For CNVs, especially, it is necessary to
apply methods based on both read depth and read pairs.
Similarly, implementing multiple de novo SNV callers16
Table 3. Number of Positive Mosaic Embryos per Zebrafish Assay
Construct
Positive Mosaic
Embryos
Structures with
Expression
DSCAM-1 151/207 (73%) Fb, Hb, Am, SC
DSCAM-2 129/211 (61%) Fb, Mb, Hb, SC
DSCAM-3 127/214 (59%) Fb, Mb, Hb
DSCAM-4 97/161 (60%) Fb, Hb, Am, OP
DSCAM-5 118/180 (66%) Fb, Hb, Am
DSCAM-6 80/162 (49%) Fb, Mb, Hb, Am, SC
DSCAM-7 128/182 (72%) Fb, Hb
DSCAM-8 125/174 (72%) Fb
DSCAM-9 118/189 (62%) Hb, SC
Specific brain structures with expression are indicated. Abbreviations are as
follows: Fb, forebrain; Mb, midbrain; Hb, hindbrain; Am, amacrine cells; SC,
spinal cord; and OP, plfactory placode.significantly increases sensitivity. In this study, we com-
bined the well-established practice of using a machine-
learning-based approach to discover a high-quality dataset
with the benefit of additional variants by a genotype likeli-
hood-based approach.
In our study, we had access to WES andWGS data gener-
ated with the same sequencing platform for 149 of the in-
dividuals. This comparison differs from that of a previously
published study of genome sequencing in intellectual
disability,12 where the comparison was made with very
different platforms (e.g., Complete Genomics WGS and
SOLiD WES). On the basis of our comparisons of WGS
and WES, we hypothesize that the heterogeneity in
sequencing platforms most likely led to an overestimate
of the utility of genome sequencing data, in part because
the SOLiD data had much poorer representation of the
exome (~50% fewer variants than would be expected on
the basis of more recent experiments).8,13 In addition,
the comparison presented here is more direct because we
controlled for differences in discovery methods by calling
SNVs and indels calls with the exact same software pack-
ages. Our study has found a benefit of using both WES
and WGS for discovering SNVs and indels, as in a previ-
ously reported study,13 and highlights to a much greater
extent the utility of CNV discovery within genome data
and its superiority over exome sequencing in detecting var-
iants. Although exome sequencing is very cost efficient,
we found that genome sequencing increased sensitivity
within protein-coding regions in that it recovered on
average two million more bases than WES. In particular,
this addition was in regions of higher GC content and
allowed access to additional sequence in 1,854 genes previ-
ously missed in most samples by exome sequencing. SNV
and indel calling was much more uniform in an analysis
of genome sequencing data—the only noticeable shift in
variation numbers was due to ancestry. Remarkably, the
greatest benefit came from the discovery of small CNVs
corresponding to single-exon events that cannot be reli-The Aably detected through exome sequence data.7 Importantly,
these differences are in addition to the potential impor-
tance to be derived from the vastly increased sensitivity
WGS provides over WES in analysis of noncoding tran-
scribed and intergenic sequences. Nevertheless, combining
both WES and WGS datasets achieves maximal sensitivity
in discovering variants in coding DNA sequence (CDS).
Our data suggest that integrating WES has the potential
to increase SNV yield within protein-coding regions by
5%–10%, partly because of the higher sequence coverage
afforded by WES. In lieu of combining WES and WGS,
an alternate approach would be to perform deeper WGS
sequencing,12 especially as the cost of WGS declines and
WES is ultimately abandoned.
Among the de novo mutations in the 53 families, we
discovered a 6 kb deletion of the first exon and promoter
of calnexin (CANX) in proband 14153.p1. CANX binds cal-
cium and associates with N-linked glycoproteins in the
endoplasmic reticulum, where it is thought to function
as a molecular chaperone. The gene is highly expressed
in human neurons derived from induced pluripotent
stem cells59 and has been predicted to be a protein-protein
interaction hub associated with de novomutations in indi-
viduals with schizophrenia.60 Interestingly, this particular
affected female individual has the highest burden of de
novo mutations (n ¼ 3) in this study and might be an
example of the female protective effect, whereby the devel-
opment of autism requires a higher genetic burden.61,62 In
another family (13874), we discovered a larger de novo
duplication (52 kb) affecting multiple exons of SUMO-acti-
vating enzyme unit 1, SAE1. SAE1 encodes one of the
key proteins associated with the sumoylation pathway,63
which plays a role, amongmany others, in neuronal differ-
entiation and synapse formation.64 Remarkably, four addi-
tional individuals carrying duplications of this locus have
been reported previously in autism,65,66 suggesting that a
recurrent duplication might be associated with autism
risk (Figure S16). We also discovered de novo missense mu-
tations in genes associated with the glutamate receptor
excitatory pathway in proband 13951.p1 (GRIA1 [MIM:
138248]) and proband 14370.p1 (GNAI1 [MIM: 139310]),
as well as de novo mutations in two genes (CHRND
[MIM: 100720] and SUV420H1 [MIM: 610881]) in proband
11729.p1 and a severe missense mutation (c.323G>A
[p.Arg108His]) in the first exon of PIK3CA, missed by
exome sequencing, in proband 11804.p1. Missense muta-
tions of this gene have been previously associated with
megalencephaly-capillary malformation-polymicrogyria
(MCAP syndrome [MIM: 602501]),67 megalencephaly,
hemimegalencephaly, and focal cortical dysplasia.68,69
The autistic proband in this case was macrocephalic with
a head circumference of 62 cm (5.6 SDs above the
mean70) and a height of 147 cm (age 10 years).
Among potential inherited risk variants, we discovered
that a private deletion of the promoter and first exon of
WNT7A was transmitted maternally to a male proband
(12793.p1). This CNV was only detected by read-pairmerican Journal of Human Genetics 98, 58–74, January 7, 2016 69
analysis and was probably missed by WES because of its
size (2 kb) and very high GC content (~79%). WGS read-
depth analysis, SNP microarray, and aCGH validation
failed to detect or validate this event. PCR and sequencing
of the breakpoints were the only experimental methods
that confirmed the deletion. WNT7A is a critical gene in
both cell proliferation and Wnt signaling; it has been
implicated in diverse neuronal processes, including neural
stem cell renewal, synapse formation, axon guidance, and
neuronal progenitor cell progression.71 Whereas only the
proband has a diagnosis of autism, both the proband and
his mother have macrocephaly, and the proband has com-
plications of gastrointestinal dysfunction—phenotypes
seen in other genes associated with Wnt signaling.72 We
also identified that a small deletion (14 kb) within noncod-
ing putative regulatory DNA of DSCAM was transmitted
from the mother to the male proband in family 11572.
DSCAM is one of two genes associated with neurocognitive
dysfunction with Down syndrome (MIM: 190685), and
multiple de novo and inherited CNVs disrupting this
gene have been reported among cases of autism.7,45 For
this particular deletion, 19% of the locus is characterized
as DNase I hypersensitive, representing open chromatin;
we hypothesize that the deletion is likely to have an effect
on gene regulation. The proband in this family has a
history of seizures—a phenotype also found inmice homo-
zygous for loss-of-function mutations in this gene.73 In
addition, our modeling in zebrafish showed that nine of
nine tested CNS DNase I hypersensitive sites drive expres-
sion in vivo in the CNS (Figure 7 and Figure S17). We also
found that a 40 kb noncoding putative regulatory duplica-
tion upstream of the gene TRIO was transmitted from the
mother to themale proband in family 13539.TRIO encodes
a rho-guanine nucleotide exchange factor and has been
observed to be disrupted by new mutations in children
with autism and intellectual disability.57,74 Although this
deletion does not affect exons, we note that 8% of the locus
is DNase I hypersensitive and carries a robust H3K27AC
signal, demarcating active regulatory elements.10 Although
validating the effect of these smallerCNVswill require addi-
tional functional work, the association between such
private or de novo damaging events and genes already
implicated in autism makes them particularly appealing
candidates. Most of the smaller CNVs associated with
autism risk in this study were transmitted from the mother
to the male proband, consistent with the maternal trans-
mission bias observed for large CNVs and now inherited
private gene-disruptive SNVs in autism.7,61,75
In five (~10%) families, we identified probands carrying
multiple high-risk mutations, potentially consistent with a
more complex oligogenic model of autism risk.76 Autism
proband 11712.p1, for example, carries a maternally in-
herited 120 kb genic deletion of DISC1, a gene strongly
associated with schizophrenia (MIM: 181500) and bipolar
disorder (MIM: 125480)77,78—as well as a 35 kb paternally
inherited private intronic deletion of MBD5 (MIM:
611472), a gene previously implicated in neurodevelop-70 The American Journal of Human Genetics 98, 58–74, January 7, 20mental disorders.79,80 In male proband 13122.p1, we
identified two large private CNVs within the introns of
neurodevelopmental genes NTM (MIM: 607938)81) and
RBFOX182–84 (Figure 6). One female autistic proband,
13825.p1, carries a de novo missense mutation in IKBIP
(MIM: 609861), in addition to a maternally inherited dele-
tion of SNX2 (MIM: 605929) and paternally inherited
29 kb deletion involving a portion of the 50 UTR of SNRPN
(MIM: 182279), a maternal imprinted gene associated with
Prader-Willi syndrome.85 In another female proband,
11709.p1, we found three rare, private deletions affecting
neurodevelopmental genes. These include two maternally
inherited deletions, a 12 kb intronic deletion of ARID1B,
and a 120 kb deletion mapping within 5 kb of SCN2A, as
well as a 30 kb paternally inherited rare exonic deletion
of CACNA2D4 (MIM: 608171). The latter CNV is signifi-
cantly more abundant in individuals with pediatric devel-
opmental delay and autism spectrum disorders than in
control individuals (OR ¼ 2.75, p ¼ 0.03).43 These findings
suggest that smaller CNVs affecting single exons and regu-
latory elements in genes associated with dosage imbalance
and autism risk will be an important area of focus for future
investigation.Accession Numbers
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